| Identification | Back Directory | [Name]
FITC-εAhx-Gly-Arg-Gly-Asp-Ser-Pro-OH | [CAS]
2022956-44-9 | [Synonyms]
FITC-εAhx-Gly-Arg-Gly-Asp-Ser-Pro-OH
L-Proline, N-[6-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)amino]thioxomethyl]amino]-1-oxohexyl]glycyl-L-arginylglycyl-L-α-aspartyl-L-seryl- | [Molecular Formula]
C49H59N11O16S | [MOL File]
2022956-44-9.mol | [Molecular Weight]
1090.13 |
| Chemical Properties | Back Directory | [density ]
1.60±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
3.31±0.20(Predicted) | [color ]
Yellow to orange | [Sequence]
{FITC-εAhx}-Gly-Arg-Gly-Asp-Ser-Pro |
| Hazard Information | Back Directory | [Uses]
FITC-Ahx Gly Arg Gly Asp Ser Pro is a GRGDSP (HY-P0290) coupled to FITC. GRGDSP is an integrin inhibitor that can inhibit the adherence of tumor cells to endothelial cells of blood vessels and limit its metastasis[1]. | [References]
[1] Qian J, et al. Transarterial administration of integrin inhibitor loaded nanoparticles combined with transarterial chemoembolization for treating hepatocellular carcinoma in a rat model. World J Gastroenterol. 2016 Jun 7;22(21):5042-9. DOI:10.3748/wjg.v22.i21.5042 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|